Phase 2 Evidence and Impact Analysis
Article 1 — Muranen et al. — Multi-modal data integration in ovarian cancer (PMID: 42400003)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Rigorous multi-omics integration with organoid functional validation; the 58% false-positive rate quantification for nominally pathogenic variants is a striking, actionable finding that advances precision oncology workflows meaningfully |
| Clinical Relevance | 8 | Directly informs clinical genomic testing practice; reduces false-positive actionable calls in HGSC and validates NF1/MEK axis; organoid-confirmed drug sensitivity bridges bench to clinic |
| Population Reach | 6 | HGSC is the most lethal gynecologic cancer (~250,000 global deaths/year) but the precision oncology workflow applies to the subset receiving genomic testing |
| Implementation Speed | 6 | WGS+transcriptome integration requires infrastructure investment but components exist; near-term in high-resource centers with molecular tumor boards |
| Evidence Strength | 7 | Well-powered multi-omics cohort (n=335), functional organoid validation, PMC open access; observational design limits causal claims; no prospective outcomes data yet |
Key quantitative result: >40% actionable alterations (ESCAT Tier II-III); 58% false-positive rate without transcriptional support; NF1/MEK sensitivity confirmed in patient-derived organoids.
External validation: Organoid validation is internal; independent cohort replication not reported.
Main limitation: Retrospective observational design; no prospective clinical trial demonstrating improved patient outcomes from the workflow; single-institution cohort (Finland/Italy).
Equity implications: WGS+transcriptome integration requires sophisticated infrastructure unavailable in most LMICs and community settings; findings most immediately benefit patients at high-resource academic centers. Women with HGSC in lower-income settings gain least near-term benefit.
Evidence Maturity: Validated ✓ (confirmed — functionally validated biomarker workflow, not yet practice-changing pending prospective outcome data)
Article 2 — Zhang et al. — Neoantigen-pulsed dendritic cells in GBM (PMID: 42401550)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Personalized neoantigen-pulsed DC immunotherapy in GBM is a genuinely novel approach; applying individualized neoantigen selection to DC vaccines represents meaningful advance over generic tumor lysate vaccines |
| Clinical Relevance | 7 | GBM has extreme unmet need (median OS ~15 months with standard of care); Phase Ib safety + preliminary activity in newly-diagnosed GBM is clinically meaningful, though sample size not stated and efficacy is preliminary |
| Population Reach | 5 | GBM is rare (~15 per 100,000/year) but carries catastrophic prognosis and lacks effective alternatives; scored relative to unmet need (high within small absolute population) |
| Implementation Speed | 3 | Personalized neoantigen DC manufacturing is logistically complex; requires WGS, HLA typing, peptide synthesis, autologous cell expansion — manufacturing scale-up is a major barrier; 5–10 years minimum |
| Evidence Strength | 6 | Phase Ib design establishes safety but lacks power for efficacy conclusions; sample size not reported in abstract; no control arm; published in Nature Communications (high-quality venue) |
Key quantitative result: Safety confirmed; preliminary anti-tumor activity reported — quantitative response data not specified in abstract.
External validation: Single Phase Ib trial, no independent replication.
Main limitation: Phase Ib, no control arm, small and unspecified N, efficacy data are preliminary signals only; manufacturing complexity limits generalizability.
Equity implications: Highly personalized autologous manufacturing process makes this extremely resource-intensive; if approved, access would initially be restricted to specialized academic centers, raising significant equity concerns for patients in non-academic or LMIC settings.
Evidence Maturity: Exploratory ✓ (confirmed — promising early-phase signal, not yet validated)
Article 3 — Jones et al. — ctDNA profiling for MPNST in NF1 (PMID: 42401714)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First integrated multi-class ctDNA assay (SNVs+indels+CNAs+SVs) specifically designed and validated for MPNST detection; no comparable tool existed; 80-day lead time over imaging is a landmark result |
| Clinical Relevance | 9 | MPNST is uniformly lethal at metastasis with no approved targeted therapy; distinguishing MPNST from benign NF1-associated neurofibromas is the central diagnostic challenge; this assay directly addresses it with AUC 0.917 |
| Population Reach | 6 | NF1 affects |
| Implementation Speed | 5 | Cross-validated internally but requires independent prospective validation; liquid biopsy infrastructure exists in reference labs; regulatory pathway for rare disease diagnostics may be faster; 3–5 years realistic |
| Evidence Strength | 7 | n=82 with cross-validation across three patient classes; AUC 0.917 vs 0.737 for comparator; 80-day relapse lead-time detection and molecular remission data are compelling; limited by internal validation only |
Key quantitative result: AUC 0.917 (integrated) vs. 0.737 (off-target CNA alone); relapse detected 80 days before imaging; molecular clearance with remission demonstrated.
External validation: Internal cross-validation only; no independent prospective cohort.
Main limitation: Single-institution cross-validated cohort; n=82 is small even for a rare disease; no prospective clinical utility data demonstrating intervention benefit from early detection.
Equity implications: NF1 disproportionately affects patients diagnosed in childhood who may have limited access to specialty NF centers; liquid biopsy testing requires infrastructure not universally available; patients in LMICs and rural areas remain underserved. The extreme rarity means rare disease advocacy groups are critical for access pathways.
Evidence Maturity: Validated ✓ (analytically validated; clinical utility pending prospective study)
Article 4 — Haj Saleh et al. — CD19 CAR-T in R/R follicular lymphoma (PMID: 42401099)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CAR-T in follicular lymphoma is established; this meta-analysis consolidates existing trial data — incremental value rather than conceptual novelty |
| Clinical Relevance | 8 | ORR 93.5% / CRR 84.5% in R/R FL is exceptionally high; provides highest-quality evidence synthesis to support treatment guidelines and formulary decisions |
| Population Reach | 6 | FL is the most common indolent lymphoma (~15,000–20,000 US cases/year); R/R subset is smaller; CAR-T eligibility further narrows the pool |
| Implementation Speed | 8 | CAR-T therapy for FL is FDA-approved (axicabtagene ciloleucel, lisocabtagene maraleucel); this meta-analysis directly supports implementation already underway |
| Evidence Strength | 7 | PROSPERO-registered systematic review of 6 studies; pooled ORR/CRR with 95% CIs; abstract-only access limits assessment of heterogeneity handling |
Key quantitative result: ORR 93.5% (95% CI 86.3–98.3%); CRR 84.5% (95% CI 72.6–93.6%); CRS any grade 61.4%; neurological events 33.6%.
External validation: Meta-analysis aggregates multiple trial datasets; PROSPERO registration ensures methodological rigor.
Main limitation: Only 6 studies included; abstract-only access prevents full assessment of study heterogeneity, publication bias, or follow-up duration adequacy.
Equity implications: CAR-T therapy requires specialized centers (certified treatment centers), limiting access in rural and underserved regions. The cost (~$400,000+) is a major barrier in lower-income countries. Robust efficacy data may support expanded payer coverage.
Evidence Maturity: Validated ✓ (confirmed)
Article 5 — Spiazzi et al. — Time to benefit of incretin therapies in HFpEF (PMID: 42401228)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GLP-1RA benefit in HFpEF is established (STEP-HFpEF, SUMMIT trials); quantifying time-to-benefit is a novel analytical lens that adds clinical decision-making value |
| Clinical Relevance | 8 | Time-to-benefit data is practically essential for adherence counseling, treatment initiation timing, and trial design — fills a real clinical information gap |
| Population Reach | 9 | HFpEF/HFmrEF with obesity is one of the largest and fastest-growing cardiovascular patient populations globally (millions in high-income countries, growing in LMICs) |
| Implementation Speed | 9 | GLP-1RAs are already prescribed; this meta-analysis provides immediately applicable data to guide existing prescribing; no new regulatory steps needed |
| Evidence Strength | 7 | Meta-analysis of RCTs is strong design; time-to-benefit methodology requires transparent event-time modelling; abstract-only limits full assessment |
Key quantitative result: Time-to-benefit characterization across clinical endpoints — specific time windows not extractable from abstract.
External validation: Derived from published RCTs (STEP-HFpEF, SUMMIT, etc.); method-dependent on underlying trial data quality.
Main limitation: Abstract-only access; time-to-benefit analyses require careful event-driven statistical handling; indirect comparisons between agents may inflate apparent differences.
Equity implications: Semaglutide/tirzepatide cost is substantial; benefits primarily patients in high-income health systems with GLP-1RA coverage. Adiposity-related HFpEF is prevalent in lower-income populations who may have least access to these medications.
Evidence Maturity: Potentially Practice-Changing (revision upward from Validated — this specific time-to-benefit data fills an actionable clinical gap for drugs already in use)
Article 6 — Freudenberg et al. — GPT-5 vs. FDA-cleared AI-CDS in breast cancer (PMID: 42400697)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First rigorous blinded multicenter head-to-head benchmarking of a general-purpose LLM vs. FDA-cleared specialized AI-CDS in breast cancer; challenges foundational assumptions in clinical AI regulation |
| Clinical Relevance | 7 | 96.4% top-choice rating for GPT-5 across rater-case combinations has direct implications for AI procurement, deployment, and regulatory frameworks in oncology |
| Population Reach | 8 | Breast cancer is the most common cancer in women globally (~2.3 million new cases/year); AI-CDS for breast cancer treatment planning affects a massive population |
| Implementation Speed | 5 | Regulatory, liability, and data privacy barriers to deploying general-purpose LLMs for clinical decision support are substantial; findings will drive policy debate more than rapid adoption |
| Evidence Strength | 6 | Rigorous blinded design across 7 centers is methodologically strong; BUT only 20 standardized cases — likely insufficient to capture edge cases, rare presentations, or real-world workflow performance; abstract-only |
Key quantitative result: GPT-5 Thinking ranked top choice in 96.4% of rater-case combinations across all evaluation categories.
External validation: 7-center blinded design provides multi-site validation; 20 cases is a critical limitation.
Main limitation: Only 20 standardized cases — a cherry-picked or unrepresentative case mix could meaningfully distort results; real-world performance with complex, ambiguous cases not tested; abstract-only access.
Equity implications: If general-purpose LLMs outperform expensive specialized AI tools, this could democratize clinical decision support by reducing procurement costs. However, data privacy regulations (GDPR, HIPAA) may prevent deployment in many healthcare settings, disproportionately restricting access in heavily regulated environments while unregulated settings adopt faster.
Evidence Maturity: Validated (confirmatory multicenter, but small case set warrants further study before practice change)
Article 7 — Tatangelo et al. — Taginostat HDAC6 inhibitor in CLL (PMID: 42400850)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel quinolone scaffold HDAC6 inhibitor with a newly characterized STAT4/p66Shc apoptotic mechanism; mechanistically distinct from existing BTK inhibitors and venetoclax |
| Clinical Relevance | 3 | Non-human study (primary cells + xenograft); Clinical Relevance capped at 5 per protocol; given medium confidence and preclinical-only data, 3 is appropriate |
| Population Reach | 5 | CLL is the most common leukemia in adults in the Western world; unmet need exists in R/R BTK-resistant setting |
| Implementation Speed | 2 | Preclinical only; IND-enabling studies, Phase I design, and first-in-human trials are years away |
| Evidence Strength | 5 | Primary patient CLL cells + xenograft model is a meaningful preclinical package but lacks clinical data; medium classification_confidence; abstract-only |
Key quantitative result: STAT4 expression restored; xenograft tumor growth significantly suppressed — quantitative metrics not available from abstract.
External validation: None at clinical level; preclinical only.
Main limitation: Preclinical only; no pharmacokinetic/pharmacodynamic or tolerability data in humans; mechanism not yet clinically validated.
Equity implications: If developed, HDAC inhibitor therapies face cost-access challenges similar to other targeted agents. CLL disproportionately affects older adults who may tolerate novel agents differently.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 8 — Akbar et al. — ANN/CBC for black lung disease detection (PMID: 42400964)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CBC-based ML for occupational lung disease is not fully novel but application to Indonesian coal miners with longitudinal data and specific predictor identification (eosinophils/monocytes) adds value |
| Clinical Relevance | 5 | Occupational health screening application; directly applicable to at-risk populations but not a broadly transformative clinical finding |
| Population Reach | 7 | Millions of coal miners globally in developing economies (China, Indonesia, India) with significant pneumoconiosis burden; occupational health screening gap is real and large |
| Implementation Speed | 6 | CBC is universally available; ANN deployment requires IT integration but no new testing; regulatory pathway for occupational screening tools is less demanding than diagnostics |
| Evidence Strength | 5 | n=807 longitudinal dataset is reasonable but internal validation only; no external prospective validation; medium classification_confidence; retrospective design |
Key quantitative result: High internal predictive performance (specific AUC not stated in abstract); 13.9% cumulative incidence of pneumoconiosis over 8 years; eosinophils and monocytes top predictors.
External validation: Internal only; no external validation cohort.
Main limitation: Internal validation only; generalizability to other coal mining populations or geographic settings unestablished; no clinical utility study demonstrating that early ML-flagged detection improves outcomes.
Equity implications: Strongly positive for equity — targets an underserved, high-risk industrial workforce in LMICs with limited access to sophisticated pulmonary testing. CBC is universally available even in low-resource occupational health settings.
Evidence Maturity: Validated (analytically validated internally; clinical utility pending external validation)
Article 9 — Li et al. — GLP-1RAs in adolescent obesity (PMID: 42401410)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First network meta-analysis in adolescent obesity with GLP-1RA comparison; novelty is analytical rather than mechanistic |
| Clinical Relevance | 7 | Pediatric obesity is a global epidemic; semaglutide is FDA-approved for adolescents ≥12; comparative efficacy data directly informs prescribing and guideline development |
| Population Reach | 8 | Adolescent obesity affects ~340 million children and adolescents globally; GLP-1RA eligibility in this group is rapidly expanding |
| Implementation Speed | 7 | Semaglutide already approved for adolescents; this NMA supports existing prescribing decisions immediately |
| Evidence Strength | 6 | 17 RCTs with 1,230 adolescents; Bayesian NMA is appropriate methodology; BUT most active-treatment comparisons are indirect, limiting confidence in agent rankings; abstract-only; medium confidence |
Key quantitative result: Semaglutide 2.4 mg SC associated with largest weight reduction (-18.00 kg); dulaglutide 1.5 mg largest HbA1c reduction (-1.50%).
External validation: NMA aggregates 17 published RCTs; indirect comparison networks are inherently less certain than head-to-head evidence.
Main limitation: Indirect comparisons dominate; sparse head-to-head data limits confidence in agent rankings; long-term safety in adolescents not assessed.
Equity implications: Pediatric obesity disproportionately affects low-income and minority communities; GLP-1RA costs (~$1,000+/month without insurance) create access disparities. Findings most directly benefit adolescents in well-resourced healthcare systems.
Evidence Maturity: Validated ✓ (confirmed — highest-quality comparative data available for this population)
Article 10 — Kim et al. — Deep learning ECG for AMI with XAI (PMID: 42401625)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | DL ECG for AMI is a well-trodden field; the dual validation of diagnostic accuracy AND educational XAI utility is a meaningful but incremental advance |
| Clinical Relevance | 6 | Relevant to both clinical deployment and training; XAI educational validation is underexplored and adds genuine value beyond diagnostic accuracy alone |
| Population Reach | 8 | AMI is one of the leading causes of death globally; ECG-based diagnosis applies universally |
| Implementation Speed | 5 | DL ECG tools require EHR integration and regulatory clearance; XAI for training has fewer barriers but institutional adoption takes time |
| Evidence Strength | 5 | Sample size not stated; single-institution likely; DL model development study without prospective clinical validation; medium confidence; PMC open access |
Key quantitative result: High diagnostic accuracy for AMI — specific metrics not extractable from available metadata.
External validation: Not established from available data.
Main limitation: Sample size unknown; DL model development and validation studies frequently show performance degradation in external deployment; XAI educational validation methodology not fully assessable from abstract.
Equity implications: ECG is universally available; AI-powered ECG analysis could benefit remote and resource-limited settings but requires reliable connectivity and hardware for deployment.
Evidence Maturity: Validated (internally; prospective clinical deployment validation needed)
Article 11 — Li et al. — Exercise, FGF21, adiponectin in older women (PMID: 42401082)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Exercise benefits on adiponectin are well-established; FGF21 modulation by exercise in this context is more novel but not groundbreaking |
| Clinical Relevance | 6 | RCT design with older women and metabolic syndrome endpoints is clinically informative; supports existing exercise prescriptions with biomarker mechanistic data |
| Population Reach | 7 | Older women with metabolic syndrome constitute a large and growing global population |
| Implementation Speed | 9 | Exercise is immediately prescribable; no regulatory, cost, or infrastructure barriers |
| Evidence Strength | 6 | RCT design is strong; sample size not specified; abstract-only; medium confidence; biomarker associations don't establish clinical outcome improvement |
Key quantitative result: Significant increases in FGF21 and adiponectin with exercise; independently associated with reduced metabolic syndrome components — quantitative effect sizes not extractable.
External validation: Single RCT; no independent replication.
Main limitation: Sample size unknown; biomarker changes don't directly demonstrate improved clinical outcomes (CV events, mortality); women-only limits generalizability.
Equity implications: Exercise prescriptions are low-cost and universally accessible; this finding is inherently equitable. Older women globally, including in LMICs, can benefit. Structured exercise programs may require community infrastructure.
Evidence Maturity: Validated ✓ (confirmed)
Article 12 — Ichimasa et al. — Competing mortality and surgery for T1 CRC in older adults (PMID: 42400343)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Competing risk framework applied to T1 CRC surgical decision in older adults is well-timed and challenges widely practiced guideline-directed care; novel quantification of the net benefit question |
| Clinical Relevance | 8 | Directly challenges standard of care recommendation for surgery post-endoscopic resection in older multimorbid patients; relevant to thousands of annual clinical decisions |
| Population Reach | 7 | T1 CRC following endoscopic resection is a common scenario; the aging population drives increasing case volume globally |
| Implementation Speed | 7 | Competing risk frameworks can be applied immediately; changes in clinical practice require guideline committee deliberation but no new technology needed |
| Evidence Strength | 6 | Systematic review with competing risk modelling is methodologically strong; sample size not specified; abstract-only; medium confidence; retrospective data underlying the model |
Key quantitative result: Net benefit of additional surgery substantially reduced when competing non-cancer mortality is incorporated — specific quantitative thresholds not extractable from abstract.
External validation: Systematic review aggregates multiple datasets; competing risk model parameters may vary across population contexts.
Main limitation: Competing risk model is only as good as the mortality data inputs; surgery recommendations depend heavily on individual comorbidity burden which may not be granularly captured.
Equity implications: Older patients in underserved settings may have higher competing mortality risk (greater comorbidities, less surgical access), making this finding even more applicable to them; paradoxically, resource-limited settings already under-operate, so the clinical message aligns with equity-driven deintensification.
Evidence Maturity: Potentially Practice-Changing (revision upward — directly challenges active guideline recommendations with competing risk evidence)
Article 13 — Cabezas et al. — Awareness program reduces diagnostic delay in primary hyperoxaluria (PMID: 42401963)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Awareness-reduces-delay framework is well established in rare diseases; this is a well-executed national example rather than a conceptual breakthrough |
| Clinical Relevance | 7 | Primary hyperoxaluria progresses to ESRD without early diagnosis; reducing diagnostic odyssey has direct therapeutic consequences, especially now that lumasiran (approved RNAi therapy) requires early initiation for maximum benefit |
| Population Reach | 4 | Ultra-rare (estimated 1–3/million); scored higher relative to unmet need and applicability of the awareness model to hundreds of other rare diseases |
| Implementation Speed | 8 | Educational awareness programs are immediately replicable at low cost; no regulatory or infrastructural barriers; model is exportable |
| Evidence Strength | 6 | National cohort with pre-post comparison is meaningful; no control group (no comparator nation/region); sample size not specified; medium confidence |
Key quantitative result: Significant reduction in diagnostic delay — specific delay reduction quantified but not extractable from abstract.
External validation: Single-country pre-post design; no comparator region.
Main limitation: No control population; pre-post design susceptible to secular trends; France's healthcare infrastructure may limit generalizability to other countries.
Equity implications: Patients with rare diseases globally face prolonged diagnostic odysseys (average 5–7 years); awareness programs are low-cost and replicable in diverse settings. However, ultra-rare disease awareness depends on specialist access — patients in rural or LMIC settings may not reach the specialists needed for genetic diagnosis.
Evidence Maturity: Validated ✓ (confirmed — well-executed national evidence for a replicable model)
Article 14 — Cazaubiel et al. — BCMA bispecific antibodies after GPRC5D therapy in myeloma (PMID: 42401497)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Sequential bispecific antibody use (GPRC5D → BCMA) is a genuinely emerging clinical question with limited prior evidence; real-world data fills a prospective trial gap |
| Clinical Relevance | 6 | Important for R/R myeloma management in the era of multiple bispecific targets; classification_confidence=low reduces certainty of score |
| Population Reach | 6 | Multiple myeloma: ~35,000 US cases/year; R/R patients with prior bispecific exposure are a growing subset |
| Implementation Speed | 7 | Both agent classes are already available; findings directly inform sequencing decisions already being made |
| Evidence Strength | 4 | Retrospective real-world study with low classification confidence (largely title-inferred); sample size unknown; abstract partially reviewed — significant uncertainty applies per scoring rules |
Key quantitative result: Durable responses with BCMA bispecific after GPRC5D therapy — specific response rates not extractable.
External validation: Not established; single retrospective cohort.
Main limitation: Low classification confidence; abstract partially retrieved; retrospective design with undefined patient selection; no comparison arm.
Evidence Maturity: Validated (downgraded confidence due to classification_confidence=low; treat as preliminary real-world signal)
Article 15 — Lee et al. — Tumor-agnostic biomarkers in lymphoma (review) (PMID: 42401005)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Identifies a strategic gap (tumor-agnostic trials excluding lymphoma) clearly and systematically; framing around FDA-approved targets is current and useful |
| Clinical Relevance | 5 | Narrative review; no new clinical data; calls for action rather than demonstrating direct impact |
| Population Reach | 6 | Lymphoma encompasses multiple subtypes affecting ~100,000 new US cases/year; identifying understudied targets could benefit many |
| Implementation Speed | 3 | Review identifying a gap has indirect implementation; requires trial design, enrollment, regulatory review before any practice change |
| Evidence Strength | 4 | Narrative review; no systematic methodology; medium confidence; open access |
Key quantitative result: Systematic enumeration of FDA-approved tumor-agnostic targets not studied in lymphoma.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 16 — Liu et al. — ASCT for PCNSL, Taiwan registry (PMID: 42401521)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Non-thiotepa conditioning comparability is a practical finding of moderate novelty; adds real-world data to limited literature |
| Clinical Relevance | 6 | Directly informs practice in centers without thiotepa access (relevant globally, especially in Asia) |
| Population Reach | 4 | PCNSL is rare (~1,500 US cases/year); limited population reach |
| Implementation Speed | 7 | Non-thiotepa conditioning already used; findings immediately applicable to treatment planning |
| Evidence Strength | 5 | n=65; retrospective registry; small sample limits statistical confidence despite reasonable OS data |
Evidence Maturity: Validated ✓ (confirmed — real-world registry evidence)
Article 17 — He et al. — SLC7A11/PD-L1 co-expression in ENKTL (PMID: 42400641)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Novel mechanistic hypothesis linking ferroptosis resistance (SLC7A11) and immune checkpoint (PD-L1) co-expression as a prognostic/therapeutic axis in ENKTL |
| Clinical Relevance | 5 | Prognostic marker with therapeutic implications; small n=42; no clinical intervention data |
| Population Reach | 3 | ENKTL is ultra-rare and geographically concentrated (East/Southeast Asia, Latin America) |
| Implementation Speed | 3 | No validated therapeutic targeting yet; early translational stage |
| Evidence Strength | 5 | IHC in n=42 + GEO external validation is meaningful but small; retrospective; abstract-only |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 18 — Mroueh et al. — SGLT2i+GLP-1RA synergy in CAD (PMID: 42401896)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Ex vivo human CAD tissue data demonstrating synergistic mechanism is more compelling than purely in vitro work; M1 monocyte-driven endothelial dysfunction axis is mechanistically specific |
| Clinical Relevance | 4 | Non-human/ex vivo study; Clinical Relevance capped at 5 per protocol; mechanistic rationale supports combination therapy but no clinical outcome data |
| Population Reach | 8 | CAD is one of the leading causes of death globally; SGLT2i+GLP-1RA combination is widely prescribed |
| Implementation Speed | 5 | Provides mechanistic rationale for a combination already in clinical use; won't change prescribing alone but supports ongoing clinical trials |
| Evidence Strength | 5 | Ex vivo CAD patient tissue is a meaningful translational model; but no randomized clinical evidence for the synergy claim; medium confidence |
Evidence Maturity: Exploratory ✓ (confirmed — mechanistic rationale, no clinical outcome evidence)
Article 19 — Huang et al. — Insulin resistance indices in NAFLD/MASLD (PMID: 42401883)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Comparative IR index analysis in NAFLD/MASLD is methodologically incremental; the cardiometabolic-liver nexus is well-studied |
| Clinical Relevance | 6 | Identifying the best IR index for CV risk stratification in NAFLD/MASLD has immediate clinical tool implications |
| Population Reach | 8 | NAFLD/MASLD affects ~25% of adults globally; the CV complication burden is enormous |
| Implementation Speed | 7 | IR indices are calculable from routine clinical data; no new testing required |
| Evidence Strength | 6 | Multicenter prospective cohort is relatively strong; specific IR winner and sample size not extractable; medium confidence |
Evidence Maturity: Validated ✓ (confirmed)
Article 20 — Yago et al. — Primary care and early cancer detection, Japan (PMID: 42401800)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Pathway-to-stage analysis in primary care is useful but not conceptually novel; key finding (pancreatic/hepatobiliary cancers remain hard to catch early) is well known |
| Clinical Relevance | 6 | 14-year real-world data across 29 cancer types informs primary care practice and cancer screening policy |
| Population Reach | 7 | Primary care cancer detection is universally relevant; findings applicable to population-level screening policy globally |
| Implementation Speed | 6 | Policy implications are actionable but require healthcare system-level changes |
| Evidence Strength | 6 | Large real-world dataset (267,313 consultations, 347 cancers, 14 years); retrospective; single clinic; medium confidence |
Evidence Maturity: Validated ✓ (confirmed)
Article 21 — Veleva et al. — CASK iPSC models (PMID: 42400957)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First patient-derived iPSC models for CASK-related intellectual disability; enables mechanistic work and drug screening not previously possible in human cells |
| Clinical Relevance | 2 | In vitro only; Clinical Relevance capped at 5 for non-human studies; early tool generation with no direct patient impact yet |
| Population Reach | 4 | Ultra-rare; scored relative to high unmet need |
| Implementation Speed | 2 | Lab-stage resource; 10+ years to any therapeutic impact |
| Evidence Strength | 4 | iPSC characterization study; methodologically sound for its scope; in vitro only; abstract-only |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 22 — Tian et al. — Perioperative imatinib duration in GIST (PMID: 42401066)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Imatinib in GIST is established; duration optimization adds practical real-world value |
| Clinical Relevance | 7 | Duration of perioperative imatinib is an active clinical question; nationwide real-world data informs practice where prospective evidence is lacking |
| Population Reach | 5 | GIST is uncommon (~5,000 US cases/year); relevant to that specific population |
| Implementation Speed | 7 | Findings are directly applicable to current prescribing decisions |
| Evidence Strength | 5 | Nationwide registry is large but retrospective; sample size not specified; abstract-only; medium confidence |
Evidence Maturity: Validated ✓ (confirmed)
Article 23 — Xin et al. — EBV-BRCA1-GPX4 ferroptosis resistance in B-cell lymphoma (PMID: 42401412)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel EBNA1-BRCA1-GPX4 axis connecting EBV immune evasion to ferroptosis resistance is mechanistically creative and previously undescribed |
| Clinical Relevance | 3 | Cell line + xenograft only; capped at 5 per non-human rule; no primary patient cells |
| Population Reach | 5 | EBV+ B-cell lymphomas are geographically enriched but affect patients globally; subset of lymphoma |
| Implementation Speed | 2 | Preclinical only; 5–10+ years to any clinical application |
| Evidence Strength | 4 | Cell lines + xenograft; no primary patient cells; abstract-only; medium confidence |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 24 — de Oliveira et al. — Lyn-deficient EV proteomics in CLL (PMID: 42401775)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | EV proteomics in CLL TME with CD248 as candidate target is interesting but primarily hypothesis-generating |
| Clinical Relevance | 3 | Preclinical mixed model; capped at 5 |
| Population Reach | 5 | CLL is common but this is early-stage research |
| Implementation Speed | 2 | Preclinical book chapter; very early |
| Evidence Strength | 3 | Book chapter (limited peer review rigor vs. journal), mixed models, abstract-only, medium confidence |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 25 — Ntaganda et al. — Digital CHW-led NCD screening in Rwanda (PMID: 42401860)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CHW-led digital health programs are not conceptually novel; Rwanda implementation adds important real-world scaling evidence |
| Clinical Relevance | 5 | Hypertension detection matters enormously but this is an implementation/public health study without direct patient outcome data |
| Population Reach | 8 | Sub-Saharan Africa has enormous unaddressed NCD burden; scalable CHW model applicable across LMICs |
| Implementation Speed | 7 | Program is already operating; findings directly support scale-up and replication in other LMIC settings |
| Evidence Strength | 5 | Implementation study with measurable outcomes; sample size not stated; observational; no comparator; medium confidence |
Evidence Maturity: Validated ✓ (confirmed — implementation evidence)